- Gilead Sciences (NASDAQ:GILD) agrees to buy MYR GmbH and its new hepatitis drug for €1.15B ~($1.4B) in cash plus a potential future milestone payment of up to €300M.
- MYR's Hepcludex (bulevirtide) was conditionally approved by the European Medicines Agency in July for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease, and the company has since launched Hepcludex in France, Germany and Austria.
- Gilead has been using its considerable cash reserves to make a series of acquisitions and partnerships over the past year to boost its product pipeline, including its $21B purchase in September of breast cancer medication maker Immunomedics.
- https://seekingalpha.com/news/3643283-gilead-buys-german-maker-of-hepatitis-drug-in-1_4b-deal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.